Cu(C4HI6N4)][Ni(CN)4], Mr = 346'5, triclinic, Pi, a=6.460(9), b= 7.230(10), c= 7.864 (15)A, a = 106.81 (13), /3 =91"51 (14), y= 106.94 (12) °, V= 333"9 (9) A 3, Z= 1, O m = 1"71 (1), Dx=1"723Mgm -3, A(MoKa)=0-71069A, /x= Abstract. [V¢(C12H10N6)(CO)4], Mr---534.14, monoclinic, P2Jc, a=15.327(2), b=13.993(2), c= * To whom correspondence should be addressed. 0108-2701/91 / 112448-04503.00 18.526 (2)/~, fl = 114.00 (1) °, V = 3629.7 (9)/~3, Z= 8, Dx = 1.95 Mg m -3, ,~(Mo Ka) = 0.71073/~, /z = 6.535 mm-1, F(000) = 2032, T = 298 K, R (wR) = 0.023 (0.030) for 5538 unique observed reflections [I

No abstract

No abstract

Diastereoselective reduction ThienoquinolizidinePhenanthroquinolizidine alkaloids a b s t r a c tThe stereoselective synthesis of epi-thieno analogues of the phenanthroquinolizidine bioactive alkaloids (À)-Cryptopleurine and (À)-(15R)-Hydroxycryptopleurine was achieved in five steps starting from easily available enantiopure (S)-2-aminoadipic acid used as chiral pool and nitrogen atom source. During these investigations, both p-cationic cyclization of chiral N-thienylmethyl-6-oxopipecolinic acids into pure (S)keto-lactams and theirs regioselective and diastereoselective reduction, considered as key steps of this sequence, were studied. Of particular interest, the FriedeleCrafts cyclization using (CF 3 CO) 2 O/BF 3 $Et 2 O show that near the expected keto-lactams, enamides and enamidones containing trifluoromethyl residue were isolated. A mechanism leading to the latter products with high synthetic potential was discussed.

No abstract